572 related articles for article (PubMed ID: 23039887)
21. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
22. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells.
Hsu FJ; Komarovskaya M
J Immunother; 2002; 25(6):455-68. PubMed ID: 12439343
[TBL] [Abstract][Full Text] [Related]
23. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
Qian J; Hong S; Wang S; Zhang L; Sun L; Wang M; Yang J; Kwak LW; Hou J; Yi Q
Blood; 2009 Oct; 114(18):3880-9. PubMed ID: 19654406
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
Hájek R; Butch AW
Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
[TBL] [Abstract][Full Text] [Related]
25. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
26. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
28. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
29. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
[TBL] [Abstract][Full Text] [Related]
30. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
31. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
32. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Yi Q; Desikan R; Barlogie B; Munshi N
Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
34. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
[TBL] [Abstract][Full Text] [Related]
35. Tocotrienols are good adjuvants for developing cancer vaccines.
Hafid SR; Radhakrishnan AK; Nesaretnam K
BMC Cancer; 2010 Jan; 10():5. PubMed ID: 20051142
[TBL] [Abstract][Full Text] [Related]
36. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
37. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
[TBL] [Abstract][Full Text] [Related]
38. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses.
Muraro S; Bondanza A; Bellone M; Greenberg PD; Bonini C
Blood; 2005 May; 105(9):3596-604. PubMed ID: 15650058
[TBL] [Abstract][Full Text] [Related]
39. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
